New PET scan agent aims to better detect rare tumors
NCT ID NCT04888481
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new radioactive imaging agent called 68Ga-HA-DOTATATE to see if it can safely and accurately detect neuroendocrine tumors using PET/CT scans. About 600 people with known or suspected tumors will receive the agent and be followed for one year. The goal is to improve diagnosis compared to older methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Alberta
RECRUITINGEdmonton, Alberta, T6G 2B7, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can trained immune cells outsmart brain tumors?
- Can the Body's own immune cells beat a recurrent brain tumor?
- Do Younger-Age pancreatic tumors behave differently? a new study digs in
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Can AI read tumor slides to outsmart childhood cancer?